{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T23:04:25Z","timestamp":1756076665825,"version":"3.40.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Stroke and Cerebrovascular Diseases"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jstrokecerebrovasdis.2016.12.015","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T18:18:09Z","timestamp":1485281889000},"page":"1041-1046","source":"Crossref","is-referenced-by-count":5,"title":["Impact of Tissue Plasminogen Activator Dosing on Patients Weighing More Than 100\u2009kg on 3-Month Outcomes in Acute Ischemic Stroke"],"prefix":"10.1016","volume":"26","author":[{"given":"Jeffrey","family":"Garavaglia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Yetzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Regier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3757-6164","authenticated-orcid":false,"given":"Matthew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"CDC","key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0010"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0015","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group","volume":"333","author":"Aa","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0020","unstructured":"Alteplase [package insert]. South San Francisco, CA. Genetech USA; 2015."},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0025","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0030","first-page":"1","article-title":"Prevalence of obesity among adults and youth: United States, 2011-2014","volume":"219","author":"Ogden","year":"2015","journal-title":"NCHS data brief"},{"author":"Aa","key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0035"},{"year":"2013","series-title":"R: A language and environment for statistical computing","author":"R Core Team","key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib9000"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0040","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1161\/01.STR.23.5.632","article-title":"Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes","volume":"23","author":"Brott","year":"1992","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0045","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1161\/01.STR.23.5.641","article-title":"Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset","volume":"23","author":"Haley","year":"1992","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0050","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1001\/jama.2014.732","article-title":"Prevalence of childhood and adult obesity in the United States, 2011-2012","volume":"311","author":"Ogden","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0055","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000175766","article-title":"Does body weight influence the response to intravenous tissue plasminogen activator in stroke patients?","volume":"27","author":"Lou","year":"2009","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0060","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1212\/01.wnl.0000317092.21210.e6","article-title":"Metabolic syndrome and resistance to IV thrombolysis in middle cerebral artery ischemic stroke","volume":"71","author":"Arenillas","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0065","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1161\/STROKEAHA.108.531079","article-title":"The metabolic syndrome is associated with a higher resistance to intravenous thrombolysis for acute ischemic stroke in women than in men","volume":"40","author":"Arenillas","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0070","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1161\/STROKEAHA.108.546564","article-title":"Sex-differences in the impact of metabolic syndrome on tissue plasminogen activator-induced recanalization","volume":"40","author":"Tsivgoulis","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0075","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1161\/STROKEAHA.110.599613","article-title":"Impact of obesity on stroke outcome after intravenous thrombolysis","volume":"42","author":"Sarikaya","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0080","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1161\/STROKEAHA.110.603514","article-title":"Is the maximum dose of 90\u2009mg alteplase sufficient for patients with ischemic stroke weighing >100\u2009kg?","volume":"42","author":"Diedler","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0085","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.01.022","article-title":"Is there a decreased risk of intracerebral hemorrhage and mortality in obese patients treated with intravenous thrombolysis in acute ischemic stroke?","volume":"22","author":"Hassan","year":"2013","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0090","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000328813","article-title":"Outcome of intravenous thrombolysis in stroke patients weighing over 100\u2009kg","volume":"32","author":"Sarikaya","year":"2011","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0095","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jstrokecerebrovasdis.2011.11.003","article-title":"Relationship of obesity to recanalization after hyperacute recombinant tissue-plasminogen activator infusion therapy in patients with middle cerebral artery occlusion","volume":"21","author":"Deguchi","year":"2012","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0100","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1007\/s10753-011-9397-2","article-title":"The role of PAI-1 and adiponectin on the inflammatory state and energy balance in obese adolescents with metabolic syndrome","volume":"35","author":"Corgosinho","year":"2012","journal-title":"Inflammation"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0105","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1161\/01.STR.0000137608.73660.4c","article-title":"Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator","volume":"35","author":"Ribo","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0110","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","article-title":"Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators","volume":"352","author":"Hacke","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0115","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1001\/jama.282.21.2019","article-title":"Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. the ATLANTIS study: a randomized controlled trial. alteplase thrombolysis for acute noninterventional therapy in ischemic stroke","volume":"282","author":"Clark","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0120","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1161\/01.STR.31.4.811","article-title":"The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators","volume":"31","author":"Clark","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0125","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1161\/01.STR.23.5.646","article-title":"Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke","volume":"23","author":"von Kummer","year":"1992","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0130","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3171\/jns.1991.74.5.0808","article-title":"Tissue plasminogen activator thrombolysis of a middle cerebral artery embolus in a patient with an arteriovenous malformation. Case report","volume":"74","author":"Jafar","year":"1991","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0135","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/01.STR.0000227191.01792.e3","article-title":"Alteplase at 0.6\u2009mg\/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT)","volume":"37","author":"Yamaguchi","year":"2006","journal-title":"Stroke"},{"author":"CDC","key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0140"},{"author":"US Census Bureau","key":"10.1016\/j.jstrokecerebrovasdis.2016.12.015_bib0145"}],"container-title":["Journal of Stroke and Cerebrovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305716306127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305716306127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T18:25:06Z","timestamp":1536085506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1052305716306127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1052305716306127"],"URL":"https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2016.12.015","relation":{},"ISSN":["1052-3057"],"issn-type":[{"type":"print","value":"1052-3057"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}